OptiNose

OptiNose — Q3 2018 Earnings Presentation

17 slides from OptiNose's earnings presentation, Nov 13, 2018

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 13, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Optinose Key Priorities

    Optinose Key Priorities Accelerate XHANCE® prescription growth Advance our clinical program for XHANCE for a follow-on indication for the treatment of chronic sinusitis Support our commercial and development objectives through efficient use of capital ■ ~$220 Million of cash as of September 30, 2018

  4. Slide 4: XHANCE Launch Update

    XHANCE Launch Update optinose

  5. Slide 5: Examples of Positive XHANCE Physician Feedback

    Examples of Positive XHANCE Physician Feedback * “The polyps were significantly reduced and patient symptoms improved. The results were dramatic.” - ENT *Testimonials and images reflect real life experience of those who have reported using XHANCE. However, they are individual results and results do

  6. Slide 6: Our Updated Patient Assistance Program Addresses Physician Perceptions Regarding Affordability and Access

    Our Updated Patient Assistance Program Addresses Physician Perceptions Regarding Affordability and Access XTENDED Patient Support .$0 co-pay for initial Rx for all commercial patients .Maximum out of pocket of $30 for refills for covered commercial patients .Maximum out of pocket of $50 for non- cov

  7. Slide 7: Additional Commercial Updates

    Additional Commercial Updates Market Access . Nationally, we believe more than 75% of commercial lives are in a plan where XHANCE is covered in a Tier 3 formulary position* . Recently signed first Part D contract and expanding Medicaid coverage Writers . More than 3,800 physicians have written a pre

  8. Slide 8: XHANCE Monthly Prescription Volumes

    XHANCE Monthly Prescription Volumes New promotional materials and patient affordability program rolled out week of August 17 +42% XHANCE 5,000 4,880 4,000 3,450 3,440 3,360 3,191 3,081 3,000 2,225 2,000 1,000 806 0 Mar Apr May Jun Jul Aug Sep Oct Market TRx for Intranasal Steroids increased 10% from

  9. Slide 9: XHANCE Weekly Prescription Volumes

    XHANCE Weekly Prescription Volumes New promotional materials and patient affordability program rolled out week of August 17 1600 +28% +22% 4,552 1236 1200 3,568 1117 1124 1075 2,932 1004 910 893 841 811 830 800 749 712 714 698 639 664 611 600 400 0 Jul 06 Jul 13 Jul 20 Jul 27 Aug 03 Aug 10 Aug 17 Au

  10. Slide 10: Q3 2018 Financial Update

    Q3 2018 Financial Update optinose—

  11. Slide 11: Financial Review – Third Quarter 2018: Revenues and Average Revenue per Prescription

    Financial Review – Third Quarter 2018 Q3 2018 Revenues and Average Revenue per Prescription ($ 000’s) Revenues $1,902 . Average revenue of ~$191 per TRx in Q3 increased 33% compared to average revenue of $1,274 ~$144 per TRx in Q2 . Increase is primarily attributable $865 to lower rates of utilizati

  12. Slide 12: Financial Review – Fourth Quarter and Full Year 2018 Operating Expenses

    Financial Review – Fourth Quarter and Full Year 2018 Full year 2018 Operating Expenses expected to be in the range of $112M to $115M - prior range was $117M to $121M ($M) Operating Expenses $78.7 $25.1 Q3 2018 YTD 2018 12

  13. Slide 13: Pipeline Update and Closing Remarks

    Pipeline Update and Closing Remarks

  14. Slide 14: XHANCE: Chronic Sinusitis Follow-on Indication (sNDA)

    XHANCE: “Chronic Sinusitis” Follow-on Indication (sNDA) Met with FDA Selection of CRO First patient regarding CS and study expected to enroll study design locations in 4Q 2018 Chronic Sinusitis trial design expected to include co-primary endpoints: both an objective measure of inflammation and a sub

  15. Slide 15: Emerging Growth Company with Approved Products

    Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY XHANCE® presents a significant opportunity in the ENT/Allergy market with the current indication XHANCE offers “pipeline within a product” opportunities Additional business development expected to focus

  16. Slide 16: Investor Relations

    Investor Relations – NASDAQ: OPTN At 30 September 2018: Analyst Coverage1 – ~$220 million in cash BMO: Gary Nachman – Long-term debt: $75 million – 41.2 million common shares o/s Jefferies: David Steinberg – 8.0 million options & warrants o/s Cantor Fitzgerald: William Tanner Optinose Investor Conta

  17. Slide 17: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 13, 2018

OptiNose — Q3 2018 Earnings Presentation on 6ix